{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22"}]}],"title":"Homozygous FF- Phenylalanine"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}],"title":"Heterozygous FV- Valine/Phenylalanine"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Homozygous VV- Valine"}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"description":"Among patients who received 1.8mg/kg dose, the frequency of the FcγRIIIa-158 V/F polymorphism are described.","groups":[{"description":"Evaluable patients with received dose of 1.8mg/kg","id":"OG000","title":"Dose 1.8mg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"4 eligible patients did not consent for genetic studies.","reportingStatus":"POSTED","timeFrame":"From the end of first dose to the end of last dose (Up to 13 Months)","title":"Number of Patients With FcyRIIIa-158 V/F (Valine/Phenylalanine) Polymorphism","type":"SECONDARY","unitOfMeasure":"Participants"}